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Canine aortic strip studies revealed insensitivity of angiotensin II (AI&induced aortic contraction to inhibition by the non-peptide antagonist 
DuP753 @KB = 6.7kO.l). In order to determine the origin of this phenomenon we cloned the canine homologue of the AT, AI1 receptor. Expression 
of this cDNA in COS-7 cells indicated a low affinity of DuP753 for the cloned receptor (KD = 92 nM). The predicted amino acid sequence is highly 
homologous to other mammalian AT, receptors; sequence comparisons uggest the pharmacological difference may be the result of a threonine residue 
in position 163 in the IVth transmembrane domain. 
Key words; Angiotensin receptor; Non-peptide antagonists; cDNA cloning; Dog aorta; Vascular contractility; COS cell 
1. Introduction 
The renin angiotensin system has a major role in the 
regulation of salt and water metabolism and hence blood 
pressure, and there is abundant evidence of its involve- 
ment in human cardiovascular pathology. Investigation 
of its role has been facilitated in recent years by the 
development of non-peptide angiotensin receptor antag- 
onists [l]. The use of these drugs has revealed the pres- 
ence of two distinct subtypes of angiotensin receptors 
termed ATi and AT, which show selectivity for the non- 
peptide antagonist DuP753 (Losartan) and PD123 177, 
respectively [2]. 
The canine aortic strip model has been widely used in 
pharmacological studies of angiotensin and other 
vasoactive substances. In the course of investigations 
into the pharmacology of various non-peptide AT, 
angiotensin receptor antagonists we found that the ca- 
nine aortic angiotensin receptor was significantly less 
sensitive to blockade by DuP753 than the rabbit. As 
virtually all the physiological functions of angiotensin 
including aortic contraction are mediated through the 
AT, receptor in other mammals [3], it seemed most prob- 
able that the canine vasoconstrictor eceptor was a mo- 
lecular variant of the AT, receptor of other species. An 
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understanding of the molecular basis of the interaction 
of non-peptide antagonists with the receptor could be a 
valuable advantage in the design of more effective agents 
of this type, and thus we set out to clone this receptor and 
to compare its pharmacology with that observed in func- 
tional studies in dog isolated aortic strips. 
2. Materials and methods 
2.1. Functional studies in aortic strips 
Isometric tension measurements were made from endothelium de- 
nuded helical strips of rabbit or dog aorta, suspended at an initial 
tension of 0.5 g in glass baths containing physiological salt solution 
(Na+, 143.4 mM; K+, 5.9 mM; Mg’+, 0.6 mM; Ca”, 1.3 mM; Cl-, 124.5 
mM; H,PO;, 1.2 mM; SO’;, 0.6 mM; HCO,-, 25 mM; glucose, 11.1 mM) 
at 37“C. This also contained indomethacin (30 PM) and ascorbic acid 
(100 PM), and was continually gassed with 95% 045% C02. The fol- 
lowing protocol was then followed in four matched preparations of 
rabbit or dog aorta. KC1 (80 mM) was added to all tissues to determine 
the contractile viability of the preparations. Once the contraction had 
reached plateau, the tissues were washed. After a further 15 min a 
cumulative priming IO-fold concentration response curve to AI1 (O.l- 
100 nM) was constructed. After washing the preparations were allowed 
to equilibrate for a further 30 min at which point a 3-fold concentra- 
tion-response curve to AI1 was constructed. After washing, three prep- 
arations were exposed to different concentrations of DuP753 or 
PDl23177 whilst the fourth preparation acted as a time-matched vehi- 
cle control. Two hours later, in the continued presence of antagonist 
or vehicle, a final 3-fold concentration-response curve was constructed. 
Where AI1 log concentration-response curves in the presence of antag- 
onists were parallel with those observed in control preparations, AI1 
concentration ratios were calculated at the EC,, levels of the control 
curve. Antagonist pA, estimates were then made 141. Where the slope 
of the Schild regression did not differ significantly from unity, the slope 
was constrained to unity and apparent pKs values calculated. 
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2.2. Northern blot analysis 
Poly-(A)’ mRNA was prepared from various dog tissues and was 
loaded on a 1% agarose gel containing formaldehyde (6.3%) in 20 mM 
MOPS buffer @H 7.0). After electrophoresis, RNA was transferred to 
supported nitrocellulose (Amersham), baked, pre-hybridized, and hy- 
bridized for 16 hat 42°C in the presence of 50% formamide. The probes 
used were either the full-length human or canine AT, receptor cDNA 
clone, or a rat B-actin cDNA probe. Probes were labelled to high 
specific activity (>109 cpm/pg) using [‘*P]dCTP (6000 Cilmmol, Amer- 
sham) and the random hexanucleotide priming technique [5]. Blots were 
washed in 0.1 x SSC at 55 or 60°C (final wash) and subjected to autora- 
diography for 18 h to 5 days (AI1 receptor) or 1.5 h @-actin) with 
Kodak XAR-2 tilm. 
2.3. Library screening 
An oligo-dT primed canine liver cDNA library cloned in lEgtl0 was 
obtained from Clontech and approximately 250,000 plaques were 
plated and screened with a canine-derived AT, receptor probe [6]. This 
was synthesised by PCR using canine genomic DNA as template and 
oligonucleotide primers hAT,-211 (S-GCACTGGCTGACTTATGC- 
3’) and hAT,-858 (5’-GATAGGCATGGCCGTGTC-3’) based on the 
human AT1 receptor cDNA sequence [7,8]. PCR products were sepa- 
rated on a gel, and the 647 bp band excised and quantitated prior to 
being labelled as above. Three successive rounds of library screening 
were performed as described [6] and resulted in two strongly positive 
clones. The largest cDNA insert from these was excised with EcoRI and 
subcloned into the plasmid pGEM7 (Promega). 
2.4. DNA sequencing 
Double-stranded ideoxynucleotide chain termination sequencing 
with Sequenase (USBC) was performed using successive oligonucleo- 
tide primers. Sequence data was analyzed with PCGENE software 
(Intelligenetics). 
2.5. Expression vector construction and transfection 
The full-length EcoRI fragment from the pGEM clone was excised 
and inserted into the EcoRI site of the plasmid expression vector 
pcDNA1 (Invitrogen). The orientation of the insert was checked in 
transformed colonies, and the correctly orientated plasmid was used in 
transfection studies. These were performed by cationic lipid mediated 
transfection with DOTAP (Boehringer) [9] into COS-7 cells (CRL 
No. 165 1, ATCC). After transfection, cells were plated in 6-well plates 
for binding studies, which were performed 48 h after addition of the 
DNA. 
2.6. AII binding studies 
Displacement binding studies were performed on whole cells in mul- 
tiwell plates using ‘*‘I-labelled [Sar,,Ile,]-AI1 (2000 Wmmol, Amer- 
sham). Displacement was with either AII, DuP753 or PD123177 (syn- 
thesized by Glaxo Group Research), and incubations were for 60 min 
at 37°C. After washing on ice, cells were lysed in 0.1 M sodium hydrox- 
ide, scraped and counted in a multichannel gamma counter. Data were 
analyzed with LIGAND software [lo]. 
: 200- RABBIT AORTA 
a .? 
1 ao- 
C= 1 GO.- 
Qn 140.- 
=0 @E 120.- 
EO I oo.- 
_g i ao.- 
2 f 60 .- 
40.- 
ae$ 
n 20 .- 
3. Results 
AI1 (0.1-100 nM) evoked concentration-related con- 
tractions of rabbit and dog aortic strips with mean ECso 
values (95% confidence interval) of 1.8 nM (0.744) and 
3.3 nM (1.9-5.7)(n = 4-7), respectively (Fig. 1). DuP753 
acted as a competitive antagonist of the effects of AI1 in 
aortic strips from both species causing parallel concen- 
tration-related rightward displacement of the AI1 con- 
centration-response curve (Fig. 1). DuP753 also tended 
to increase the maximum response to AII. Fig. 1 illus- 
trates that DuP753 is a significantly more potent antago- 
nist of AI1 in the rabbit (mean apparent pK, = 8.4 f 0.02, 
n = 4) compared to dog aortic strips (mean apparent 
p& = 6.7 f 0.1, n = 7). In contrast to DuP753, the AT, 
antagonist PD 123 177 (1 PM) caused no inhibition of the 
effects of AI1 in rabbit or dog aortic strips. 
Northern blot analysis using the human angiotensin 
receptor as a probe with mRNA from various dog tissues 
suggested that a single AT,-like mRNA species of 2.9 kb 
was present in most tissues, but was most prevalent in the 
canine liver and adrenal. For this reason, a canine liver 
cDNA library was screened. In order to undertake high 
stringency hybridization the canine gene was amplified 
by PCR using primers based on human AT, receptor 
transmembrane domains II and VII. 
The cDNA library was screened as described and re- 
sulted in the isolation of two strongly positive plaques. 
One of these (19a) contained a 1.8 kb cDNA which was 
subcloned into pGEM7. This clone was sequenced and 
revealed a cDNA encoding a polypeptide of 359 residues 
with marked homology to other cloned AT1 receptors 
(Fig. 2). Interspecies comparison indicates that this clone 
diverges insignificantly from other mammalian AT, 
angiotensin receptors, being most similar to the porcine 
receptor (95.5% identical over the whole length). 
Use of this clone as a probe in northern blots of 
mRNA from various canine tissues indicates high preva- 
lence of this mRNA in the adrenal and liver, with smaller 
quantities in aorta, kidney, lung, testis and heart (Fig. 3). 
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Fig. 1. Antagonism of the contractile effects of AI1 in rabbit and dog aortic strips by DuP753. Rabbit aorta (AI1 in the absence, l; and presence 
of DuP753 at 0.03 PM, q ; 0.1 PM, A; and 0.3 PM, o; n = 4). Dog aorta (AI1 in the absence l; and presence of DuP753 at 0.1 PM, q ; 1.0 PM, A; 
and 10 PM, o; n = 7). Values are mean f S.E.M. 
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Fig. 2. Comparison of the amino acid sequence of the canine AT1 receptor with other mammalian AT, receptors. Identical amino acids are represented 
by (-). Potential N-linked glycosylation sites are represented by (*), and potential protein kinase C phosphorylation sites in the canine receptor by 
(0). The single letter amino acid code is used throughout. 
Confirmation that this clone is an angiotensin receptor 
and characterization of its pharmacology requires its ex- 
pression in a eukaryotic system. Therefore the full-length 
cDNA was inserted downstream of the CMV promoter 
in the plasmid pcDNA1, and this was used in transient 
expression transfection experiments in COS-7 cells, 
which we have previously found to be almost devoid of 
endogenous AT, receptor [l 11. Expression was assessed 
by binding of ‘251-labelled [Sar,,Ile,]AII 48 h after trans- 
fection. Fig. 4 illustrates the displacement curves ob- 
tained from a mean of three binding experiments in 
which either AI1 or Dup 753 was used to displace the 
labelled ligand. The Kn’s calculated by Scatchard analy- 
sis were 5.29 x lo-’ M for AI1 and 92.2 x lo-’ M for 
DuP753. The AT, specific non-peptide antagonist, 
PD123177 at a concentration of 10e6 M had no effect on 
binding. 
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Fig. 3. Northern blot analysis of various canine tissues probed with the canine AT,-like receptor cDNA probe. RNA markers are shown on the right. 
Ao = aorta, Lu = lung, H = heart, K = kidney, Ad = adrenal, L = liver, bL = human liver. 2.5 pug of poly (A)’ mRNA were loaded in each lane 
except for aorta which was 20 pg of poly (A)+ mRNA. 
4. Discussion 
Development of the non-peptide angiotensin receptor 
antagonists has resulted in a rapid expansion of our 
understanding of the role of angiotensin in physiology, 
and they have great potential value as therapeutic agents 
in the treatment of hypertension and cardiac failure. 
Since the original cloning of the rat and bovine AT, 
receptors [12,13], there has been the opportunity to un- 
derstand the molecular nature of the interaction between 
the AT,-selective non-peptide antagonists and target re- 
ceptors. This might in turn ultimately lead to the devel- 
opment of new antagonists. Clues as to the basis of this 
interaction could come from mutagenesis tudies of the 
receptor, or from functional studies of these antagonist- 
receptor interactions in other species, essentially exploit- 
ing naturally occurring ‘mutagenesis’ experiments. The 
discovery that DuP753 has low affinity for AT, receptors 
in functional studies in dog aortic strips provided the 
basis for this study. 
Our cloning and sequencing studies reveal that the 
canine receptor has a sequence that is remarkably similar 
to that of the AT, receptor of other mammalian species, 
being 95.5% identical at the amino acid level to the por- 
cine sequence over its entire length. The sequence pre- 
dicts the existence of a number of potential protein ki- 
nase C phosphorylation sites in the third intracellular 
loop (one site) and in the C-terminal tail (four sites), and 
three potential N-linked glycosylation sites in identical 
positions to those of the other mammalian AT, receptors 
(see Fig. 2). 
When expressed in COS-7 cells the canine receptor 
exhibits very similar pharmacology to the bovine [12,14] 
and porcine receptor [16,17] in terms of its high affinity 
for AII, insensitivity to PD123177, and reduced affinity 
for DuP753 when compared with the rat, results which 
are consistent with the canine aortic strip studies. Thus 
the aortic strip studies yielded an estimated Ka of 199.5 
nM for DuP753 which is similar to the calculated Kr, of 
92.2 nM. However comparison of the canine, bovine and 
porcine receptor sequences reveals little that is common 
between them yet different from the other DuP753 sensi- 
tive receptors. The only obvious common feature in a 
location that might be involved in DuP753 binding is the 
threonine at position 163 in the IVth transmembrane 
domain which is an alanine in other receptors (see 
Fig. 2). Domain swapping and mutagenesis experiments 
could be used to determine the role of the molecular 
differences between the canine and other receptors in 
their interaction with non-peptide antagonists. 
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Fig. 4. Displacement of ‘Z51-labelled [Sar,,Ile,]-AI1 with angiotensin II 
(0) and DuP753 (0). These results represent he mean displacement 
from three binding experiments, and error bars represent he S.E.M. 
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